Aggregator
Precision indole skeletal editing for single-carbon replacement
Science, Volume 392, Issue 6797, Page 512-518, April 2026.
A helper NLR channels organellar calcium to trigger plant immunity
Science, Volume 392, Issue 6797, Page 499-505, April 2026.
Peer influence decay and behavioral diffusion in adolescent networks: A simulation approach
Science, Volume 392, Issue 6797, Page 506-511, April 2026.
Performance of a large language model on the reasoning tasks of a physician
Science, Volume 392, Issue 6797, Page 524-527, April 2026.
Apparent Hack’s law in river deltas
Science, Volume 392, Issue 6797, Page 493-498, April 2026.
Anticipating the future in an algorithmic age
Science, Volume 392, Issue 6797, Page 472-472, April 2026.
Scientist as Subject
Science, Volume 392, Issue 6797, Page 472-472, April 2026.
Disneyland’s factory-inspired future
Science, Volume 392, Issue 6797, Page 471-471, April 2026.
A hidden map in your nose could explain how smell works
Scientists have finally cracked one of the biggest mysteries in the senses: how smell is organized. By mapping millions of neurons in mice, researchers discovered that smell receptors in the nose aren’t random at all—they’re arranged in neat, overlapping stripes based on receptor type, forming a hidden structure scientists never knew existed. Even more striking, this layout mirrors how smell information is mapped in the brain, revealing a coordinated system from nose to neural circuits.
First-ever 3D view shows how killer T cells destroy cancer
The body’s “killer” T cells don’t just attack—they strike with astonishing precision, forming a tiny, highly organized contact zone that lets them destroy dangerous cells without harming their neighbors. Now, scientists have captured this process in unprecedented detail, revealing a hidden world of molecular choreography.
Tiny probes make sense of abnormal bursts in the epileptic brain
“Spikes” hijack neurons involved in cognition—and can be predicted up to 1 second in advance
Deepfakes are everywhere. The godfather of digital forensics is fighting back
Hany Farid, who's spent his career building tools to detect fake images, is facing his biggest challenge yet: AI
AI is starting to beat doctors at making correct diagnoses
Large language model excels at clinical decisions, even in fast pace of a simulated ER
AI helps create bacterium that’s partially missing a universal amino acid
Advance could suggest new ways to synthesize proteins with bespoke functions in medicine and biotechnology
After outcry, European funder reverses abrupt rule change restricting resubmissions
Decision from the European Research Council comes after more than 1000 scientists signed open letter decrying plans
Enigmatic muscle may help explain penguins’ signature waddle
Find also reveals how the birds keep their bodies streamlined when underwater
‘Modern European family’ predates fall of Rome, DNA reveals
Painstaking pedigrees hint at origins and social norms of people living near Rome’s northern frontier
Battle over DNA within fertilized eggs may explain why some IVF procedures fail
Temporarily keeping parents’ genetic contributions separate promotes normal development, mouse study suggests
The role of ultrasound in addressing neurodegenerative diseases: A review of mechanisms, applications, and challenges
With the aging of the global population, neurodegenerative diseases have become a major public health challenge. Currently, there are many limitations in the traditional treatment of neurodegenerative diseases, such as medicine, deep brain stimulation, transcranial magnetic stimulation, and transcranial direct current stimulation, including the inability to penetrate the blood-brain barrier (BBB) accurately and challenges in achieving precise and quantitative control during the treatment...
Serious side effects of Alzheimer's immunotherapy demand scrutiny
Monoclonal antibodies targeting amyloid-β, i.e., lecanemab and donanemab, have recently been approved for treating early Alzheimer's disease (AD). Though these antibodies are by many considered milestones in AD therapy, clinical approvals have been inconsistent due to ongoing debates over their clinical benefit and safety. The reported cognitive decline slowing is modest and often below the thresholds for clinically significant differences on outcome scales. Moreover, these therapies are linked...